New Blood Signature Predicts Future Lung Cancer

In June 2026, researchers identified a novel 14-protein blood signature that can predict an individual’s risk of developing lung cancer more than five years before diagnosis, opening new possibilities for early detection and preventive intervention.

Key Points

Large-Scale Analysis: Scientists analysed more than 48,000 blood samples to identify biomarkers associated with future lung cancer risk.
Validation: The findings were validated using eight international datasets, including data from both smokers and non-smokers.
Underlying Mechanism: The protein signature appears to reflect an altered inflammatory environment in the lungs that develops before cancer forms, rather than signals originating from an existing tumour.
Pre-Disease Phase: The study highlights a previously underappreciated pre-cancer inflammatory stage, creating opportunities for early intervention before the disease develops.
Current Challenge: Lung cancer remains the leading cause of cancer-related deaths worldwide, and existing screening programmes are largely restricted to older individuals with a history of smoking.